Campus SLB

Unterstützte Projekte

Campus SLB unterstützt Projekte in verschiedenen Phasen

Projektinitialisierung

Folgende Projekte wurden bei der Ethikkommission/Swissmedic eingereicht:

Prof. Dr. med. Hubert Nötzli
Überprüfung der Langzeit-Indikationsqualität der chirurgischen Hüftdislokation für die Behandlung eines femoroacetabulären Impingement

Prof. Dr. med. Markus Borner
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer (RESCUE)

Dr. med. Dominik Böhlen
Prostate Cancer Outcomes - Compare & Reduce Variation in DKG-zertifizierten Prostatakrebszentren

Dr. med. Yves Brühlmann
A multicenter, observational cohort study of women undergoing Immediate breast Reconstruction following MAstectomy (IRMA)

Prof. Dr. med. Markus Mohaupt
Swiss Stroke Register

PD Dr. med. Richard Nyffeler
Can Vitamin C reduce the risk of postoperative shoulder stiffness after shoulder operations? A mono-center, double-blinded, randomized and placebo-controlled study.


Projektumsetzung

Folgende Projekte werden bereits umgesetzt. 

PD Dr. med. Gilles Berclaz

  • Tailored AXIllary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer A multicenter randomized phase III trial. (TAXIS: SAKK 23/16 / IBCSG 57-18 / ABCSG-53)
  • Effect of quilting sutures on post-operative drainage after mastectomy and/or axillary lymph node dissection in patients with breast cancer: a single blind randomised phase III controlled trial (BZ01/17)

Prof. Dr. med. Markus Borner

  • Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 in patients with bone metastases from castration resistant prostate cancer or from breast cancer (SAKK 96/12 REDUSE)
  • Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial (SAKK 41/13)
  • Pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer (IBCSG 48-14 Positive)